Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

• QTCF at the 1-hour postinfusion time point (Cmax) [ Time Frame: Cycle Day 2 ] [ Designated as safety issue: Yes ]
• Complete Response (CR) rate [ Time Frame: 24 to 32 weeks (six planned 28-day cycles plus two optional 28-day cycles) ] [ Designated as safety issue: No ]
  as measured by the revised response criteria for malignant lymphoma defined by the International Working Group (IWG)
• Overall Response Rate (ORR) [ Time Frame: 24 to 32 weeks (six planned 28-day cycles plus two optional 28-day cycles) ] [ Designated as safety issue: No ]
  ORR = Complete Response [CR] + Partial Response [PR], as measured by the revised response criteria for malignant lymphoma defined by the IWG
• Safety and tolerability of bendamustine and rituximab administration [ Time Frame: 24 to 32 weeks (six planned 28-day cycles plus two optional 28-day cycles) ] [ Designated as safety issue: Yes ]
  through evaluation of adverse events, serum chemistry panels, vital signs measurements, physical examination findings, and Eastern Cooperative Oncology Group (ECOG) performance status

The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).

• Non-Hodgkin's Lymphoma
• Mantle Cell Lymphoma

• Drug: bendamustine
  Bendamustine at 90 mg/m2 iv on days 1 and 2
• Drug: Rituximab
  Rituximab at 375 mg/m2 iv on day 1 of a 28-day cycle.

Key Inclusion Criteria:

• Histopathologic confirmation of one of the following CD20+ B-cell non-Hodgkin's lymphomas. Tissue diagnostic procedures must be performed within 6 months of study entry and with biopsy material available for review:

  • follicular lymphoma (grade 1 or 2)
  • immunoplasmacytoma/immunocytoma (Waldenstrom's macroglobulinemia)
  • splenic marginal zone B-cell lymphoma
  • extra-nodal marginal zone lymphoma of mucosa associated lymphoid tumor (MALT) type
  • nodal marginal zone B-cell lymphoma
  • mantle cell lymphoma

• Meets one of the following need-for-treatment criteria (with the exception of mantle cell lymphoma for which treatment is indicated):

  • presence of at least one of the following B-symptoms:

    1. fever (>38ºC) of unclear etiology
    2. night sweats
    3. weight loss of greater than 10% within the prior 6 months
  • large tumor mass (bulky disease)
  • presence of lymphoma-related complications, including narrowing of ureters or bile ducts, tumor-related compression of a vital organ, lymphoma induced pain, cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or ascites
  • hyperviscosity syndrome due to monoclonal gammopathy
• CD20 positive B cells in lymph node biopsy or other lymphoma pathology specimen.
• No prior treatment. Patients on "watch and wait" may enter the study if a recent biopsy (obtained within the last 6 months) is available.

• Adequate hematologic function (unless abnormalities related to lymphoma infiltration of the bone marrow or hypersplenism due to lymphoma) as follows:

  • hemoglobin of >= 10.0 g/dl
  • absolute neutrophil count (ANC) >= 1.5 x 10 9th power/L
  • platelet count >= 100 x 10 9th power/L
• Bidimensionally measurable disease (field not previously radiated).
• Able to provide written informed consent.
• ECOG performance status <= 2.
• Estimated life expectancy >= 6 months.
• Serum creatinine of <= 2.0 mg/dL or creatinine clearance >= 50 mL/min.
• ALT and AST ≤ 2.5 x ULN, and alkaline phosphatase and total bilirubin within normal limits.
• Left ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP.
• A medically accepted method of contraception to be used by women of childbearing potential (not surgically sterile or at least 12 months naturally postmenopausal).
• Men capable of producing offspring and not surgically sterile must practice abstinence or use a barrier method of birth control.

Key Exclusion Criteria:

• Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade 3 follicular lymphoma.
• Transformed disease. Bone marrow blasts are permitted, however, transformed disease indicating leukemic involvement is not permitted.
• Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma.
• Prior radiation for NHL, except for a single course of locally delimited radiation therapy with a radiation field not exceeding 2 adjacent lymph node regions.
• Active malignancy, other than NHL, within the past 3 years except for localized prostate cancer treated with hormone therapy, cervical carcinoma in situ, breast cancer in situ, or non-melanoma skin cancer following definitive treatment.
• New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias or unstable angina, electrocardiographic evidence of active ischemia or active conduction system abnormalities, or myocardial infarction within the last 6 months. (Prior to study entry, ECG abnormalities at screening must be documented by the investigator as not medically relevant).
• Known human immunodeficiency virus (HIV) positivity.
• Active hepatitis B or hepatitis C infection (Hepatitis B surface antigen testing required).
• Women who are pregnant or lactating.
• Corticosteroids for treatment of lymphoma within 28 days of study entry. Chronically administered low-dose corticosteroids (e.g., prednisone ≤20 mg/day) for indications other than lymphoma or lymphoma-related complications are permitted.
• Any serious uncontrolled, medical or psychological disorder that would impair the ability of the patient to receive therapy.
• Any condition which places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data.
• Any other investigational agent within 28 days of study entry.
• Known hypersensitivity to bendamustine, mannitol, or other study-related drugs.
• The patient has Ann Arbor stage I disease.
• The patient has a history of congenital long QT syndrome.
• The patient has a history of cardiac disease with significant potential for QT prolongation.
• The patient has screening electrocardiography (ECG) on day 1 of cycle 1 with QTCF interval greater than 450 ms that is confirmed by a second ECG. If the QTCF interval is greater than 450 ms on both ECGs, the ECGs will be sent to ERT, the Central ECG Reader vendor, for an overread (with 24-hour turn around time) and ERT will make a final decision on enrollment.
• The patient has serum potassium or magnesium less than the lower limit of normal.